🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9112 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Sep 2026, 03:16 UTC
9112
Studies in scope
industry-sponsored, all four open statuses
4950
Recruiting now
open to new participants
2202
Lead sponsors
across recruiting studies
Top states
California 5295 Florida 4397 Illinois 2479 Georgia 2346 Arizona 2231
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca111 Eli Lilly and Company97 AbbVie74 Merck Sharp & Dohme LLC62 Novartis Pharmaceuticals48
State
California5295 Florida4397 Illinois2479 Georgia2346 Arizona2231
All 51 states
Target enrolment
to
2231 of 9112 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Michigan, Missouri
2026-06-25
Not yet open
rTMS Device for Improvement of Obsessive and Compulsive Behaviors
NCT07679750Obsessive-Compulsive Behavior
BTL Industries Ltd.
Not applicable
60
Arizona, Florida, Massachusetts
2026-06-24
Recruiting
An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.
NCT07357597Stomatitis
AstraZeneca
Phase 4
100
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Idaho, Illinois
2026-06-24
Recruiting
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
SHY Therapeutics
Phase 1
30
Arizona, Colorado, Texas
2026-06-24
Recruiting
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
NCT07724340Adults With Overweight/Obesity and Type 2 Diabetes
Antag Therapeutics
Phase 2
150
Arizona, California, Florida, Georgia, Utah
2026-06-19
Recruiting
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
NCT07702578AML, MDS
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
NCT07632001Diabetic Foot Ulcers (DFUs), Diabetic Foot, Chronic Wounds
Reprise Biomedical, Inc.
Not applicable
180
Arizona, Florida, Massachusetts, Missouri, New York, Ohio, Oklahoma, Texas
2026-06-15
Recruiting
A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1
NCT07645287HIV-1-infection
Gilead Sciences
Phase 2
175
Arizona, California, Colorado, Florida, Georgia, Michigan, Missouri, New Jersey
2026-06-15
Recruiting
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
NCT07673900Overweight and/or Obesity
Terrestrial Bio, Inc.
Phase 1
62
Arizona
2026-06-15
Active, closed
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299Obesity, Overweight, Weight Maintenance
Verdiva Bio Dev Limited
Phase 2
120
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Illinois, Kansas
2026-06-12
Recruiting
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
NCT07104032Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Active, closed
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
NCT07656727Obesity and Cardiovascular Risk
BioAge Labs, Inc.
Phase 2
160
Arizona, Arkansas, Florida, Kentucky, Maryland, Missouri, Nevada, New York
2026-06-11
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-06-11
Recruiting
Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections
NCT07220915Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
Octapharma
Phase 3
360
Arizona
2026-06-10
Recruiting
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
NCT07682896Graves' Disease
Yarrow Bioscience, Inc.
Phase 2
232
Arizona, California, Florida, Georgia, Kentucky, Michigan, Nebraska, New York
2026-06-10
Recruiting
D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
NCT06622057Biliary Tract Cancer (BTC)
InnoPharmax Inc.
Phase 3
240
Arizona, Florida, Ohio
2026-06-09
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Immuneering Corporation
Phase 3
510
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Illinois
2026-06-05
Recruiting
A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy
NCT07675135EDS, Cataplexy, Fatigue, Narcolepsy
Harmony Biosciences Management, Inc.
Phase 3
258
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2026-06-04
Recruiting
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT07645820Atopic Dermatitis
Castle Biosciences Incorporated
Observational
450
Arizona, Maryland, Michigan, Missouri, Nevada, New Hampshire, Texas, Virginia
2026-06-04
Recruiting
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
NCT07359820FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Elevar Therapeutics
Phase 2
30
Arizona, Florida, Illinois, Massachusetts, Minnesota, New York, Texas
2026-06-04
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Minnesota
2026-06-03
Recruiting
A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
NCT07489885Psoriasis
InventisBio Co., Ltd
Phase 2
75
Alabama, Arizona, California, Florida, Georgia, Idaho, Indiana, Kentucky
2026-06-03
Recruiting
Study of ALK-001 on the Progression of Stargardt Disease
NCT07419334Stargardt Disease
Alkeus Pharmaceuticals, Inc.
Phase 3
230
Arizona, Colorado, Florida, Massachusetts, Michigan, Ohio, Pennsylvania, Texas
2026-06-03
Recruiting
Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration
NCT07630649Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.
Phase 2
15
Arizona, California, Florida, Hawaii, Illinois, New Jersey, South Carolina, Texas
2026-06-02
Recruiting
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
NCT07592273Diabetic Retinopathy
AbbVie
Phase 2/3
576
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Maine
2026-06-01
Not yet open
A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations
NCT06287918Solid Tumors With FGFR2 Alterations, Adult
3H (Suzhou) Pharmaceuticals Co., Ltd.
Phase 1
130
Arizona, Texas
2026-06
Recruiting
A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
NCT07621237Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression
Tonix Pharmaceuticals, Inc.
Phase 2
360
Arizona, California, Florida, Georgia, Illinois, Louisiana, Maryland, Massachusetts
2026-06
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
NCT07480356Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Protara Therapeutics
Phase 3
284
Arizona, Arkansas, California, Georgia, Missouri, South Carolina, Texas
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-28
Recruiting
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
NCT07559474Hepatic Insufficiency, Liver Diseases
Incyte Corporation
Phase 1
16
Arizona, Florida, Texas
2026-05-27
Recruiting
Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion
NCT07547215Sacroiliac Joint Dysfunction, Sacroiliac Joint Pain
PainTEQ, LLC
Observational
100
Arizona
2026-05-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521Ocular Myasthenia Gravis
UCB Biopharma SRL
Phase 3
120
Arizona, Illinois, New York, Ohio, Wisconsin
2026-05-27
Recruiting
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
NCT07665892Safety in Asthma Patients
Aspeya, Inc.
Phase 1
40
Arizona, California, Texas
2026-05-26
Recruiting
Clareon TruPlus Study
NCT07502456Aphakia, Astigmatism
Alcon Research
Not applicable
122
Arizona, Ohio, South Carolina, Texas, Utah
2026-05-26
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
AbbVie
Phase 3
990
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-05-22
Recruiting
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
NCT07621718Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Jersey
2026-05-22
Recruiting
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
NCT07479797Relapsed or Refractory Large B-cell Lymphoma
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Missouri
2026-05-22
Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
NCT07492641HR+/HER2- Breast Cancer
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Florida, Georgia, Illinois
2026-05-22
Recruiting
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
NCT07602582Alzheimer Disease, Dementia, Plaque, Amyloid
Eli Lilly and Company
Phase 3
550
Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana, Iowa
2026-05-22
Recruiting
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
NCT07393282High Risk Smoldering Multiple Myeloma (HR-SMM)
Regeneron Pharmaceuticals
Phase 3
270
Arizona, Georgia, Massachusetts, Michigan, Minnesota, New York, Ohio
2026-05-21
Recruiting
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT07422480Myelodysplastic Syndrome, Anemia
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Louisiana
2026-05-21
Recruiting
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
NCT07428616Meningioma
Exelixis
Phase 2
100
Alabama, Arizona, California, Florida, Louisiana, Massachusetts, Missouri, New York
2026-05-21
Recruiting
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
NCT07610005Healthy
Immunome, Inc.
Phase 1
20
Arizona
2026-05-21
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414Obesity, Type 2 Diabetes
Novo Nordisk A/S
Phase 3
2,500
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Idaho
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
NCT07527650Type 2 Diabetes Mellitus, T2DM
Hanmi Pharmaceutical Company Limited
Phase 2
180
Arizona, Florida, Georgia, Indiana, Missouri, Nebraska, Nevada, North Carolina
2026-05-18
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
Takeda
Phase 2
222
Arizona, California, Massachusetts, New York, Pennsylvania, Tennessee, Texas
2026-05-17
Recruiting
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
NCT07589608Overweight, Obesity
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
NCT07610473Major Depressive Disorder (MDD)
Draig Therapeutics Ltd
Phase 2
118
Arizona, Arkansas, California, Florida, Georgia, Illinois, Massachusetts, New York
2026-05-14
Recruiting
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549Primary Sclerosing Cholangitis
Ipsen
Phase 3
350
Arizona, California, Colorado, Indiana, Maryland, Rhode Island, South Carolina, Tennessee
2026-05-14
Recruiting
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
NCT07553429Diabetic Macular Edema
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
NCT07287098Breast Neoplasms
Eli Lilly and Company
Phase 2
600
Alabama, Arizona, California, Colorado, Florida, Georgia, Indiana, Kentucky
2026-05-13
Recruiting
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica
NCT07286214Polymyalgia Rheumatica
Sanofi
Phase 4
300
Arizona, California, Colorado, Florida, Georgia, Illinois, Maryland, Missouri
2026-05-12
Recruiting
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886Dry Eye Disease (DED)
Dompé Farmaceutici S.p.A
Phase 2
417
Arizona, California, Florida, Georgia, Indiana, Minnesota, Missouri, North Carolina
2026-05-12
Active, closed
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity
NCT07575932Overweight, Obesity, Overweight and/or Obesity, Overweight or Obesity
Pfizer
Phase 2
940
Arizona, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-11
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399Obesity or Overweight
Amgen
Phase 3
300
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Louisiana
2026-05-11
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
NCT07610837Liver Fibrosis, Hepatic Cirrhosis
AstraZeneca
Phase 2
104
Arizona, Florida, Missouri, Nevada, North Carolina, Ohio, Oklahoma, Tennessee
2026-05-07
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
Mirati Therapeutics Inc.
Phase 2
170
Arizona, California, Delaware, Florida, Kansas, Massachusetts, Minnesota, Nebraska
2026-05-06
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)
NCT07545759Irritable Bowel Syndrome, Diarrhea
Eli Lilly and Company
Phase 2
531
Arizona, California, Florida, Illinois, Indiana, Kentucky, Michigan, Minnesota
2026-05-06
Recruiting
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
NCT07606066Type 2 Diabetes
AstraZeneca
Observational
2,150
Arizona, Arkansas, California, Florida, Georgia, Illinois, Kansas, Maryland
2026-05-06
Recruiting
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)
NCT07555483Alpha 1 Antitrypsin Deficiency
Grifols Therapeutics LLC
Phase 3
40
Alabama, Arizona, California, Florida, Minnesota, Ohio, South Carolina, Texas
2026-05-05
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
Novo Nordisk A/S
Phase 3
300
Arizona, Florida, Georgia, Illinois, New York, North Dakota, Ohio, Pennsylvania
2026-05-05
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
Eli Lilly and Company
Phase 2
60
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Michigan
2026-05-04
Recruiting
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
NCT07611110Metastatic Castration-resistant Prostate Cancer
AstraZeneca
Phase 3
670
Alabama, Arizona, California, Colorado, Florida, Illinois, Louisiana, Michigan
2026-05-04
Recruiting
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
NCT07335588Lichen Sclerosus
LEO Pharma
Phase 3
652
Alabama, Arizona, California, District of Columbia, Florida, Minnesota, New York, Ohio
2026-05-01
Recruiting
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD
NCT07610395Rhinovirus Infection
Altesa Biosciences, Inc.
Phase 2
180
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2026-05-01
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2026-05
Recruiting
A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)
NCT07545772Irritable Bowel Syndrome, Constipation
Eli Lilly and Company
Phase 2
342
Arizona, California, Florida, Illinois, Indiana, Kentucky, New York, Ohio
2026-04-29
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
NCT07567846Advanced Prostate Cancer, Metastatic Prostate Cancer
Genentech, Inc.
Phase 1/2
260
Arizona, Tennessee
2026-04-29
Recruiting
An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
NCT07365332Pulmonary Arterial Hypertension
Inhibikase Therapeutics
Phase 3
486
Arizona, California, Colorado, Kansas, Kentucky, Massachusetts, Missouri, New York
2026-04-23
Recruiting
52-week Open Label Safety-Tolerability Study
NCT07369154Schizophrenia
LB Pharmaceuticals Inc.
Phase 3
900
Arizona, Arkansas, California, Florida, Georgia, Illinois, Maryland, Missouri
2026-04-23
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
NCT07285655Pulmonary Hypertension Due to Lung Disease (Disorder)
Liquidia Technologies, Inc.
Phase 3
344
Arizona, California, Colorado, Florida, Illinois, Indiana, New York, Oregon
2026-04-23
Recruiting
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
NCT07250633Severe Hepatic Impairment, Normal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)
Phase 1
20
Arizona, Florida, Texas
2026-04-23
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443Narcolepsy Type 2
Alkermes, Inc.
Phase 3
176
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522Diabetic Macular Edema
Genentech, Inc.
Phase 1
93
Arizona, California, Florida, Maryland, Pennsylvania, Tennessee, Texas, Virginia
2026-04-21
Recruiting
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
NCT07531095Small Cell Lung Cancer
Amgen
Phase 1
160
Arizona, Florida, Illinois, Minnesota, New York, Tennessee, Virginia
2026-04-21
Recruiting
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
NCT07489651Generalized Anxiety Disorder
Reunion Neuroscience Inc
Phase 2
64
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Michigan
2026-04-20
Recruiting
Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)
NCT07486960Psoriatic Arthritis
Merck Sharp & Dohme LLC
Phase 2
140
Arizona, California, Florida, Idaho, Maryland, Missouri, Nebraska, New York
2026-04-20
Recruiting
Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy
NCT07507422Chronic Pain, Intractable Pain
Medtronic
Observational
970
Arizona, California, Missouri, Texas
2026-04-17
Recruiting
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
NCT07226843Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma
Eli Lilly and Company
Phase 1
460
Arizona, California, Colorado, Florida, Georgia, Massachusetts, Minnesota, New York
2026-04-17
Recruiting
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
NCT07546500Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Arizona, California, New Jersey, Ohio, Oregon, Pennsylvania, South Dakota
2026-04-17
Recruiting
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
NCT07287670Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics
Phase 2
85
Arizona, California, Colorado, Florida, Kansas, Maryland, Massachusetts, Minnesota
2026-04-16
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late-Onset Pompe Disease (PROGRESS-GT LOPD)
NCT07282847Pompe Disease (Late-onset), Pompe Disease Late-Onset, LOPD
AskBio Inc
Phase 1/2
12
Arizona, California, New York, North Carolina, Pennsylvania, Texas, Virginia
2026-04-15
Recruiting
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
NCT07210515Complex Regional Pain Syndrome Type I
Ambros Therapeutics, Inc.
Phase 3
270
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2026-04-14
Recruiting
A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo
NCT07533019Vitiligo, Non-Segmental Vitiligo (NSV)
Eli Lilly and Company
Phase 2
66
Arizona, California, Florida, Georgia, Indiana, Massachusetts, Michigan, New Hampshire
2026-04-14
Recruiting
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
NCT07430306Systemic Lupus Erythematosus
AstraZeneca
Phase 3
245
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2026-04-13
Recruiting
A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
NCT07481630Obesity, Knee Osteoarthritis (OA)
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
Incyte Corporation
Phase 3
588
Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia
2026-04-09
Recruiting
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
NCT07519395Irritable Bowel Syndrome
GlaxoSmithKline
Phase 2
420
Alabama, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois
2026-04-08
Recruiting
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
NCT07424404Schizophrenia, Autism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-04-07
Recruiting
A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation
NCT07535112Advanced/Metastatic Colorectal Adenocarcinoma
Bayer
Phase 1
130
Arizona, California, Colorado, New York, Texas
2026-04-07
Recruiting
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
NCT07288112Refractory Melanoma
Diakonos Oncology Corporation
Phase 1/2
35
Alabama, Arizona, California, Massachusetts, New Jersey, North Carolina, Texas
2026-04-06
Active, closed
Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
NCT07497880Obesity, Overweight
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383Narcolepsy Type 1
Alkermes, Inc.
Phase 3
150
Alabama, Arizona, California, Colorado, Florida, Georgia, Kansas, Massachusetts
2026-04-06
Rows per page Showing 101–200 of 2231
Previous 1 2 3 4 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona?page=2

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.